# A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

> **NCT06838949** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 80 (estimated)

## Conditions studied

- Herombopag

## Interventions

- **DRUG:** herombopag olamine tablets

## Key facts

- **NCT ID:** NCT06838949
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838949, "A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06838949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*